These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30970266)

  • 21. Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor.
    Muntasir HA; Bhuiyan MA; Ishiguro M; Ozaki M; Nagatomo T
    J Pharmacol Sci; 2006 Oct; 102(2):189-95. PubMed ID: 17031071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin 5-HT
    Gener T; Tauste Campo A; Alemany-González M; Nebot P; Delgado-Sallent C; Chanovas J; Puig MV
    Neuropharmacology; 2019 Nov; 158():107743. PubMed ID: 31430459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action.
    Mocci G; Jiménez-Sánchez L; Adell A; Cortés R; Artigas F
    Neuropharmacology; 2014 Apr; 79():49-58. PubMed ID: 24211653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hallucinogens and Serotonin 5-HT
    López-Giménez JF; González-Maeso J
    Curr Top Behav Neurosci; 2018; 36():45-73. PubMed ID: 28677096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
    Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA
    Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin 5-HT
    García-Bea A; Miranda-Azpiazu P; Muguruza C; Marmolejo-Martinez-Artesero S; Diez-Alarcia R; Gabilondo AM; Callado LF; Morentin B; González-Maeso J; Meana JJ
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1453-1463. PubMed ID: 31734018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
    Gogos A; Kwek P; Chavez C; van den Buuse M
    J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism.
    Bishop C; Tessmer JL; Ullrich T; Rice KC; Walker PD
    J Pharmacol Exp Ther; 2004 Aug; 310(2):687-94. PubMed ID: 15044557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional and Novel Pharmacological Approaches to Treat Dopamine-Related Disorders: Focus on Parkinson's Disease and Schizophrenia.
    Perez de la Mora M; Hernandez-Mondragon C; Crespo-Ramirez M; Rejon-Orantes J; Borroto-Escuela DO; Fuxe K
    Neuroscience; 2020 Jul; 439():301-318. PubMed ID: 31349007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices.
    Ramírez MJ; Cenarruzabeitia E; Lasheras B; Del Rio J
    Brain Res; 1997 May; 757(1):17-23. PubMed ID: 9200494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
    Sullivan LC; Clarke WP; Berg KA
    Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT
    Pottie E; Stove CP
    J Neurochem; 2022 Jul; 162(1):39-59. PubMed ID: 34978711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of quipazine and m-chlorophenylbiguanide (m-CPBG) on temporal differentiation: evidence for the involvement of 5-HT2A but not 5-HT3 receptors in interval timing behaviour.
    Body S; Asgari K; Rickard JF; Zhang Z; Fone KC; Bradshaw CM; Szabadi E
    Psychopharmacology (Berl); 2005 Sep; 181(2):289-98. PubMed ID: 15864559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of novel dopamine D
    Zhang C; Li Q; Meng L; Ren Y
    J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.
    Croft HA
    J Sex Med; 2017 Dec; 14(12):1575-1584. PubMed ID: 29198512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.